Business Context and Reporting Period
This Form 8-K is filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on August 10, 2023. The filing serves to report the Company's financial results for the second quarter ended June 30, 2023, alongside recent corporate updates. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Irvine, California.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text. Consequently, no financial figures can be extracted from this document alone.
Material Changes
The filing indicates the issuance of a press release regarding Q2 2023 results and corporate updates. However, the text does not specify the nature or magnitude of any material changes compared to the prior comparable period.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in the body of this Form 8-K. The document explicitly states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, directing readers to the attached press release for full details.
Investor Verification Checklist
- Verify the specific Q2 2023 financial results (revenue, net loss, cash position) in Exhibit 99.1 (Press Release).
- Confirm the details of the "recent corporate updates" mentioned in the filing.
- Review the press release for any updated guidance or changes in the Company's operational outlook.
- Note that the registrant name in the filing is Reneo Pharmaceuticals, Inc., distinct from the name provided in the request metadata.